Bullfrog AI (US:BFRG) Globenewswire·2025-06-12 12:00Core Insights - BullFrog AI Holdings, Inc. has announced a strategic collaboration with Sygnature Discovery to enhance drug development using AI and machine learning [1][2] - This partnership is expected to generate between $15 million and $30 million in revenue for BullFrog AI through 2028 [2] Company Overview - BullFrog AI is a technology-enabled drug development company that utilizes AI and machine learning to improve the development of pharmaceuticals and biologics [1] - The company’s proprietary platform, BullFrog Data Networks™, is powered by the bfLEAP™ engine and aims to provide AI-driven data insights [1][3] Collaboration Details - The collaboration with Sygnature Discovery will introduce BullFrog Data Networks™ to Sygnature's global client base, enhancing brand recognition and user uptake [2][3] - Sygnature Discovery is a UK-based contract research organization specializing in drug discovery, and this partnership will complement their existing capabilities [4] Platform Capabilities - BullFrog Data Networks™ accelerates the exploration of complex datasets, aiding in early target identification, mechanism-of-action elucidation, patient stratification, drug repurposing, and clinical trial optimization [3] - The platform is designed to meet the needs of small to mid-sized biopharma companies, which are often underserved by current bioinformatics solutions [4]